| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLE |
Universidad Autónoma (L.M.F., C.P., J.A., J.A.C.), Hospital Universitario Infantil Niño Jesús, Departamento de Endocrinología and Unidad de Investigación, Madrid 28009, Spain; and Department of Physiology (S.L.D., A.K.H.), University of Cambridge, Cambridge CB2 3EG, United Kingdom
Address all correspondence and requests for reprints to: Dr. J. A. Chowen, Unidad de Investigación, Hospital Universitario Niño Jesús, Avenida Menéndez Pelayo, 65, 28009 Madrid, Spain. E-mail: jachowen{at}hotmail.com.
Beneficial effects of GH on memory, mental alertness, and motivation have been documented. Many actions of GH are mediated through IGF-I; hence, we investigated whether systemic administration of GH or GH-releasing peptide (GHRP)-6 modulates the brain IGF system. Treatment of adult male rats with GHRP-6 or GH for 1 wk significantly increased IGF-I mRNA levels in the hypothalamus, cerebellum, and hippocampus, with no effect in cerebral cortex. Expression of the IGF receptor and IGF-binding protein (IGFBP)-2 were not affected. Phosphorylation of Akt and Bad was stimulated in areas where IGF-I was increased, with no change in MAPK or glycogen synthase kinase-3ß. This suggests that GH and GHRP-6 activate phosphatidylinositol kinase intracellular pathways involved in cell survival in response to growth factors. Indeed, the antiapoptotic protein Bcl-2 was augmented in these same areas, with no change in the proapoptotic protein Bax. IGFBP-5, also reported to be involved in neuron survival processes, was increased mainly in the hypothalamus, suggesting a possible neuroendocrine role. In conclusion, GH and GHRP-6 modulate IGF-I expression in the central nervous system in an anatomically specific manner. This is coincident with activation of intracellular signaling pathways used by IGF-I and increased expression of proteins involved in cell survival or neuroprotection.
This article has been cited by other articles:
![]() |
N D. Aberg, I. Johansson, M. A I Aberg, J. Lind, U. E Johansson, C. M Cooper-Kuhn, H G. Kuhn, and J. Isgaard Peripheral administration of GH induces cell proliferation in the brain of adult hypophysectomized rats J. Endocrinol., April 1, 2009; 201(1): 141 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G.-S. Frutos, L. Cacicedo, C. Fernandez, D. Vicent, B. Velasco, H. Zapatero, and F. Sanchez-Franco Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1140 - E1152. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chung, E. Kim, D. H. Lee, S. Seo, S. Ju, D. Lee, H. Kim, and S. Park Ghrelin Inhibits Apoptosis in Hypothalamic Neuronal Cells during Oxygen-Glucose Deprivation Endocrinology, January 1, 2007; 148(1): 148 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Brywe, A.-L. Leverin, M. Gustavsson, C. Mallard, R. Granata, S. Destefanis, M. Volante, H. Hagberg, E. Ghigo, and J. Isgaard Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3{beta} Phosphorylation Endocrinology, November 1, 2005; 146(11): 4665 - 4672. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Gomez-Garcia, F M Sanchez, M T Vallejo-Cremades, I A G. de Segura, and E De Miguel del Campo Direct activation of telomerase by GH via phosphatidylinositol 3'-kinase J. Endocrinol., June 1, 2005; 185(3): 421 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Smith, L. Betancourt, and Y. Sun Molecular Endocrinology and Physiology of the Aging Central Nervous System Endocr. Rev., April 1, 2005; 26(2): 203 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Brown-Borg Antiaging Supplement Holds Promise to Halt Age-Related Cognitive Deterioration Experimental Biology and Medicine, May 1, 2004; 229(5): 367 - 368. [Full Text] [PDF] |
||||
![]() |
M. D. Lewis, M. Horan, D. S. Millar, V. Newsway, T. E. Easter, L. Fryklund, J. W. Gregory, M. Norin, C.-J. Del Valle, J. P. Lopez-Siguero, et al. A Novel Dysfunctional Growth Hormone Variant (Ile179Met) Exhibits a Decreased Ability to Activate the Extracellular Signal-Regulated Kinase Pathway J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1068 - 1075. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |